Clinical research

Haematology
#Biotechnology #Cancer research #Clinical research #Solid tumours #T-Cells

Research reveals the unique biological features of roginolisib 

iOnctura, a clinical stage biotechnology company developing cancer therapies, has published non-clinical research on roginolisib in the AACR journal Cancer Research Communications. Roginolisib is a first-in-class, non-ATP-competitive, allosteric modulator of PI3Kd which prevents tumour proliferation and breaks immune tolerance in patients with solid and haematological… Read More

#Cancer Research #News

NIHR Liverpool CRF - Main Bay
#Clinical research #Clinical trial #Laboratory #Liverpool #Phase I trial #Research & development

New clinical trial facility opens in Liverpool

The new Liverpool Clinical Research Facility (CRF) unit has opened at the new Royal Liverpool University Hospital thanks to £5.3m ($6.4m) funding from the National Institute for Health Research (NIHR).   The CRF will explore new treatments and vaccines for a range of diseases prevalent in Liverpool’s communities. This… Read More

#News

Clinical trials
#Breast cancer #Cancer research #Clinical research #Clinical trials #Covid-19 #Oncology

What are the top disease areas for clinical drug trials?

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, according to a recent report by analytics company Phesi. Here, we take a look at the top four disease areas and some of the key developments in 2022.  1. Breast cancer In April, Biotech ISA… Read More

#Exclusive Content

Screening patient for AMD
#Clinical research #Complement Therapeutics #Dry AMD #Gene therapy #Geographic atrophy #Ophthalmology

Non-interventional geographic atrophy study launches

Complement Therapeutics (CTx) has enrolled the first patient in its study of people diagnosed with geographic atrophy (GA).  The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future… Read More

#News

Patient having a mammogram
#Breast cancer #Cancer research #Clinical research #Clinical trials #Oncology #Phase II trial

Breast cancer still top disease area for clinical studies

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, despite a drop in activity, according to analysis from analytics company Phesi.  The company’s global analysis of all clinical trials conducted in 2022 showed that Covid-19 came second.   Three of… Read More

#Cancer Research #News

Stamp of approval
#AstraZeneca #Cancer #Chemotherapy #Clinical research #MHRA #Oncology

First-line AZ treatment for adults with biliary tract cancer approved 

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC).1 This authorisation by… Read More

#Cancer Research #News

Diversity
#Clinical research #Clinical trial design #Clinical trials #Diversity #Epidemiology #GSK #United States

Study shines a light on representation in clinical research

A diversity study has shown that clinical trials should use real world diseases epidemiology data, rather than US Census Bureau race and ethnicity data, to ensure enrolment reflects the populations affected by different diseases.  GSK’s retrospective study looked at clinical trial demographic data from 495 GSK and… Read More

#Editor's Choice #News

Testing antiviral vaccines in the lab
#Antivirals #Clinical research #Investment #Pandemic prevention

$12 million awarded for the development of antiviral therapies

Three institutions have received a share of $12 million for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.  The money was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID may… Read More

#News

#Biologics #Cell and gene therapy #Clinical research #Comment #FDA #Regulatory

The significance of FDA industry guidance on cell and gene therapies 

On 4 November 2022, the FDA’s Center for Biologics Evaluation and Research released guidance for the industry on studying multiple versions of a cellular or gene therapy (CGT) product in an early-phase clinical trial in a single disease1. This guidance finalises the draft guidance of the same title dated September… Read More

#Exclusive Content #Opinion #Regulatory

Ukraine clinical research
#Clinical research #Clinical trials #Drug discovery #Russia #Ukraine

“Nothing scares us” – Ukraine’s clinical research sector begins fearless recovery

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko, Clinical Research Director at Medical Center Ok!Clinic+ to understand the impact of… Read More

#Editor's Choice #Exclusive Content

Diversity
#Clinical research #Clinical trials #Diversity #Ethnic populations #Inclusivity

New technology aims to improve diversity in clinical trials

Medidata has launched the Intelligent Trials Diversity Module to help improve the equity of clinical trials. The module will provide site-level participant demographic data including race, sex, age, and ethnicity.  The new Intelligent Trials Diversity Module will help sponsors identify sites that are more successful at enrolling diverse patients. Read More

#News

A clinical trial
#APAC #Clinical research #Clinical trial design #Clinical trials #Drug development

Cytel hopes to accelerate drug development in APAC region

Cytel has expanded its operations into the Asia-Pacific region (APAC), with hopes of optimising clinical trial design in the area. Cytel works with its clients on various aspects of clinical trials, including statistical design, implementation and regulatory acceptance, with the aim of helping them reduce costs, shorten timelines, and better… Read More

#News

Neuron
#Clinical research #Drug discovery #Motor neurone disease

Project granted £4.25m to advance research in motor neurone disease 

Six UK universities have collectively received £4.25 million as part of a collaborative project aimed at finding new treatments for motor neurone disease (MND).  The MND Collaborative Partnership was launched by LifeArc, MND Association, MND Scotland and My Name’5 Doddie Foundation, alongside government bodies Medical Research Council… Read More

#News

#Clinical research #Drug development #Drug discovery #Supply chain

Achieving faster drug lifecycle management 

Eugene Polini, Technical Key Account Manager at Datwyler examines the challenges drug developers are facing to speed up production lifecycles and what solutions are available to them.  While people around the world hope to never see another global pandemic in their lifetimes, it is the responsibility of pharmaceutical manufacturers to… Read More

#News

#Biopharma #Clinical research #Oncology

Biomunex appoints CSO to drive oncology R&D  

Biopharma company Biomunex Pharmaceuticals has appointed a new chief scientific officer (CSO) to the company and member of its scientific advisory board.   The company has appointed Dr Simon Plyte as CSO who joins Biomunex to help strengthen its R&D strategy.   Dr Plyte brings a wealth… Read More

#News

#Clinical research #Drug targets #Microbiome

Genetic Analysis and Eurofins offer standardised GA-map test

Genetic Analysis has announced a Service Agreement with Eurofins ADME Bioanalysis, a CRO who have launched a standardised gut microbiome test (GA-map Dysbiosis Test).  Gut microbiome profiling is required as a surrogate endpoint or exploratory biomarker in clinical trials. This is due to both the impact new pharmaceuticals can… Read More

#News